ClinicalTrials.gg
CompletedNCT01534052Updated Dec 6, 2024Results posted

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

A Phase 2 interventional study of Enzalutamide in Castration-Resistant Prostate Cancer (CRPC), sponsored by Astellas Pharma Inc. Completed at 7 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2011, registered Feb 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
63rd of 125
52 · median 52
Started
2011
with 3 others
Phase 2
65 of 125
8 open now
Registered
9th of 125
by date
Lead sponsor
7 of 125
Astellas Pharma Inc

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 63rd largest by enrollment, is one of 4 that started in 2011, is one of 65 in phase 2, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.

Read the detailed description

This was a multi-center extension study in participants with prostate cancer who have completed MDV3100 treatment study to assess the long-term safety of continued administration of MDV3100, when judged by the investigator to be in the best interest of the participant. For the study duration, all participants with castration-resistant prostate cancer (CRPC) maintained androgen deprivation with a Luteinizing Hormone Releasing Hormone (LHRH) agonist/antagonist unless they underwent bilateral orchiectomy. Participants were discontinued from study drug when the continued administration of study drug was deemed to be not in the participants' best interest by the investigator based on clinical assessment. Throughout the study, safety and tolerability were assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Participants had a safety follow-up visit 30 days after their last dose of study drug. Participants that did not meet any of the discontinuation criteria were eligible to continue to receive treatment with enzalutamide in study 9785-CL-0123 [NCT02960022] upon approval and activation of the study at the participating institution. Participants who enrolled in study 9785-CL-0123 [NCT02960022] were not required to have a safety follow-up visit.

03

Conditions studied

  • Castration-Resistant Prostate Cancer (CRPC)

Browse trials for

Keywords

  • Prostate Cancer
  • Castration-Resistant Prostate Cancer (CRPC)
  • MDV3100
  • Androgen receptor signaling inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has completed a prior study with MDV3100, can be enrolled in this extension study without any interruption in study drug
  • No new abnormalities based upon physical examination, safety laboratory data, vital signs, , and other clinical assessments noted from the last visit conducted during the subject's active MDV3100 study prior to initiation of this study
  • Male subjects and their female spouses/partners who are of must be using highly effective contraception1 consisting of two forms of (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 3 months after final study drug administration. Male subjects must not donate sperm starting at Screening and throughout the study period and for at least 3 months after final study drug administration. 1Highly effective contraception is defined as:

    • Established use of oral, injected or implanted hormonal methods of contraception.
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    • Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal form/gel/film/ cream/suppository
  • Subject agrees not to participate in another interventional study while on treatment

Exclusion criteria

Exclusion Criteria:

Subject will be excluded from participation if any of the following apply:

  1. Subject has a history of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumours, , or alcoholism.
  2. Subject has a history of loss of consciousness or within 12 months prior to Day 1 of the completed preceding study.
  3. Use of the following prohibited medication/therapies:

    • Concomitant medication that likely could cause drug-to-drug interactions with MDV3100.
    • Other (than MDV3100) androgen-receptor (AR) antagonists (bicalutamide, flutamide, nilutamide).
    • therapy other than MDV3100 or investigational procedures of any kind.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.

    Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered study drug or who underwent study procedures and did not necessarily have a causal relationship with treatment. An abnormality identified during a medical test was defined as an AE only if the abnormality induced clinical signs or symptoms, required active intervention, required interruption, or discontinuation of study medication, or was clinically significant in the opinion of the investigator. An AE was defined as serious if it resulted in any of the following outcomes: Death, Was life-threatening, Persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Congenital anomaly, or birth defect, Inpatient hospitalization or prolongation of hospitalization, Other medically important event. Drug-related AEs were those assessed by the investigator as AEs whose relationship to the to the study drugs could not be ruled out.

    Time frame: From the date of the first dose of study drug to 30 days after last dose of study drug; the median duration of treatment was 392 days, and the maximum was 1926 days

07

Results

Posted Apr 27, 2018

Participant flow

The study was conducted at 1 site in the Republic of Moldova, 2 sites in South Africa and 4 sites in the United States. In order to participate, participants had to complete a prior study with enzalutamide, be in a state of at least stable disease and benefit from continued treatment with enzalutamide in the opinion of the investigator.

Participant flow — Overall Study
MilestoneEnzalutamide
Started52
Treatment received52
Completed52
Not completed0

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered study drug or who underwent study procedures and did not necessarily have a causal relationship with treatment. An abnormality identified during a medical test was defined as an AE only if the abnormality induced clinical signs or symptoms, required active intervention, required interruption, or discontinuation of study medication, or was clinically significant in the opinion of the investigator. An AE was defined as serious if it resulted in any of the following outcomes: Death, Was life-threatening, Persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Congenital anomaly, or birth defect, Inpatient hospitalization or prolongation of hospitalization, Other medically important event. Drug-related AEs were those assessed by the investigator as AEs whose relationship to the to the study drugs could not be ruled out.

Time frame:
From the date of the first dose of study drug to 30 days after last dose of study drug; the median duration of treatment was 392 days, and the maximum was 1926 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsEnzalutamide
Any TEAE43
Drug-Related TEAEs27
Deaths5
Serious TEAEs17
Drug-Related Serious TEAEs5
TEAEs Leading to Study Drug Discontinuation12
Drug-Related TEAEs Lead to Study Discontinuation5

Adverse events

Collected over From the date of the first dose of study drug to 30 days after last dose of study drug; the median duration of treatment was 392 days, and the maximum was 1926 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutimide2/52 (3.8%)17/52 (32.7%)33/52 (63.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventEnzalutimide
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/52
AstheniaGeneral disorders2/52
Spinal cord compressionNervous system disorders2/52
Acute myocardial infarctionCardiac disorders1/52
Atrial fibrillationCardiac disorders1/52
TachycardiaCardiac disorders1/52
Anal fissureGastrointestinal disorders1/52
DiarrhoeaGastrointestinal disorders1/52
Pancreatitis acuteGastrointestinal disorders1/52
ProctalgiaGastrointestinal disorders1/52
Most frequent other events
Showing 10 of 22
Most frequent other events
EventEnzalutimide
FatigueGeneral disorders14/52
ArthralgiaMusculoskeletal and connective tissue disorders7/52
Back painMusculoskeletal and connective tissue disorders7/52
Decreased appetiteMetabolism and nutrition disorders6/52
Hot flushVascular disorders6/52
ConstipationGastrointestinal disorders5/52
DiarrhoeaGastrointestinal disorders5/52
HyponatraemiaMetabolism and nutrition disorders5/52
AnaemiaBlood and lymphatic system disorders4/52
NauseaGastrointestinal disorders4/52

Baseline characteristics

The analysis population was the Safety Analysis Set (SAF), which consisted of participants who received at least one dose of enzalutamide during the extension study. This extension study's baseline was considered the original baseline from the prior parent studies with enzalutamide.

Age, Continuous
Age, Continuous(years)Enzalutamide
Geometric mean68.6 ± 7.39
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide
Female0
Male52
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enzalutamide
Hispanic or Latino0
Not Hispanic or Latino52
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enzalutamide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White47
More than one race0
Unknown or Not Reported3
Duration of Prostate Cancer
Duration of Prostate Cancer(months)Enzalutamide
Geometric mean69.4 ± 64.10
Primary Gleason Score at Initial Diagnosis
Primary Gleason Score at Initial Diagnosis(Participants)Enzalutamide
Score 315
Score 413
Score 54
Unknown20
Secondary Gleason Score at Initial Diagnosis
Secondary Gleason Score at Initial Diagnosis(Participants)Enzalutamide
Score 39
Score 414
Score 59
Unknown20
Total Gleason Score at Initial Diagnosis
Total Gleason Score at Initial Diagnosis(Participants)Enzalutamide
Score 65
Score 716
Score 81
Score 913
Unknown17

5 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • Site US107
    Aurora, Colorado 80045, United States
  • Site US104
    Chicago, Illinois 60637, United States
  • Site US105
    Pittsburgh, Pennsylvania 15215, United States
  • Site US106
    San Antonio, Texas 78253, United States
  • Site MD37301
    Chisinau, Moldova, Republic of
  • Site ZA2701
    George, 6529, South Africa
  • Site ZA2702
    Port Elizabeth, 6001, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Apr 2017, 65 months.

Results were first posted in Apr 2018, 1 year after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 65 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2012
First posted
Feb 16, 2012
StartActual
Oct 21, 2011
Primary completionActual
Apr 18, 2017
CompletionActual
Apr 18, 2017
Results first posted
Apr 27, 2018
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01534052
Collaborators
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Feb 16, 2012
Start date
Oct 21, 2011
Primary completion
Apr 18, 2017
Completion
Apr 18, 2017
Results posted
Apr 27, 2018
Last update
Dec 6, 2024

Study contacts

Clinical Study Manager
study chair · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion